A similar approach, based on the use of the 3WJ-EGFR CL4 aptamer, was used to deliver small interfering RNA (siRNA) against XBP1, a protein involved in breast cancer chemoresistance, to TNBCs, thereby sensitizing them to chemotherapy (Figure 3B). This evidence concerns the gene EGFR and breast cancer.